Skip to main content

Table 1 Antibiotics for treating patients with intra-abdominal infections based upon susceptibility. Use local antibiogram data for choosing optimal antibiotics in target population

From: Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)

Antibiotic Enterococci Ampicillin-resistant enterococci Vancomycin-resistant enterococci Enterobacteriaceae ESBL-producing Enterobactericeae Pseudomonas aeruginosa Anaerobic Gram-negative bacilli
Penicillins/Beta-lactamase Inhibitors
 Amoxicillin/clavulanate + + +
 Ampicillin/Sulbactam + + +/−
 Piperacillin/tazobactam + + +/− + +
Carbapenems
 Ertapenem + + +
 Imipenem/cilastatin +/−a + + + +
 Meropenem + + + +
 Doripenem + + + +
Fluoroquinolones
 Ciprofloxacin + +b
 Levofloxacin +/− + +/−
 Moxifloxacin +/− + +/−
Cephalosporins
 Ceftriaxone +
 Ceftazidime + +
 Cefepime + +/− +
 Ceftolozane/tazobactam + + +
 Ceftazidime/avibactam + + +
Aminoglycosides
 Amikacin c c c + + +  
 Gentamicin c c c + + +
Glycylcyclines
 Tigecycline + + + +d + +
5-nitroimidazole
 Metronidazole +
Polymyxin
 Colistimethate (Colistin) +e + +
Glycopeptides
 Teicoplanin + +
 Vancomycin + +
Oxazolidines
 Linezolid + + +
  1. a“Imipenem/cilastatin” is more active against ampicillin-susceptible enterococci than ertapenem, meropenem and doripenem
  2. bCiprofloxacin is more active against Pseudomonas aeruginosa than levofloxacin
  3. cActive in synergy with other agents
  4. dNot active against Proteus, Morganella and Providencia
  5. eNot active against Morganella, Proteus, Providencia and Serratia